Thurston Springer Miller Herd & Titak Inc. Sells 5,323 Shares of AbbVie Inc. $ABBV

Thurston Springer Miller Herd & Titak Inc. lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 74.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,825 shares of the company’s stock after selling 5,323 shares during the period. AbbVie accounts for approximately 0.8% of Thurston Springer Miller Herd & Titak Inc.’s investment portfolio, making the stock its 21st biggest position. Thurston Springer Miller Herd & Titak Inc.’s holdings in AbbVie were worth $477,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ABBV. ACT Advisors LLC. increased its holdings in shares of AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock valued at $425,000 after purchasing an additional 41 shares during the last quarter. Willner & Heller LLC lifted its position in AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after buying an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC boosted its stake in AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after buying an additional 43 shares during the last quarter. Fielder Capital Group LLC boosted its stake in AbbVie by 1.7% during the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock worth $637,000 after buying an additional 43 shares during the last quarter. Finally, Guardian Wealth Advisors LLC NC grew its holdings in AbbVie by 0.4% in the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company’s stock valued at $2,996,000 after buying an additional 43 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company’s stock.

AbbVie Stock Performance

Shares of AbbVie stock traded up $10.20 during trading hours on Wednesday, hitting $284.56. The company’s stock had a trading volume of 1,743,498 shares, compared to its average volume of 6,390,412. The stock has a market cap of $502.76 billion, a price-to-earnings ratio of 80.41, a P/E/G ratio of 1.28 and a beta of 0.24. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $284.64. The firm has a fifty day moving average of $260.41 and a 200-day moving average of $237.87.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 13.95 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive SKYRIZI Crohn’s disease data: New Phase 3 AFFIRM results showed that subcutaneous SKYRIZI generated higher clinical and endoscopic response rates than placebo in adults with moderately to severely active Crohn’s disease. The data strengthen the outlook for AbbVie’s leading immunology franchise and its ability to support long-term growth. AbbVie’s Crohn’s Disease Drug SKYRIZI Shows More Positive Results
• Positive Sentiment: Growth engines remain in focus: Recent SKYRIZI and RINVOQ updates have reinforced expectations that the therapies can offset Humira’s continuing decline. RBC also expects the products, along with Vraylar, to support a potential third-quarter revenue beat. AbbVie Poised for Q3 Top-Line Beat
• Positive Sentiment: Supportive analyst backdrop: Royal Bank of Canada reaffirmed its outperform rating, while Erste Group raised its FY2027 EPS forecast to $16.34 from $16.19 and maintained a Buy rating. These actions add to investor confidence ahead of earnings.
• Neutral Sentiment: Institutional interest is mixed: Recent filings showed substantial buying by several large institutions, although other investors reduced their positions. One AbbVie executive also sold shares, but the transaction does not appear to be a central driver of the session.
• Negative Sentiment: Valuation and execution risks remain: AbbVie trades near its 52-week high, and some valuation analysis suggests the shares may be ahead of estimated fair value. Investors also remain focused on Humira erosion, competition in immunology, and the company’s elevated growth expectations.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ABBV. Wells Fargo & Company raised their target price on AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Scotiabank lifted their price target on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Citigroup boosted their price target on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Piper Sandler upped their price objective on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Finally, UBS Group raised their price objective on shares of AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $277.18.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.